- 6park:
美國公司宣佈人類已經攻克癌症
合成的雙鏈RNA進入肝細胞後，人體內的RNAi機制便會摧毀合成的RNA和任何與之匹配的、與腫瘤生長相關的信使RNA，阻止蛋白質的繼續產生，從而使腫瘤停止生長....
據美國媒體報導，美國阿爾尼拉姆生物技術公司日前宣佈他們找到了一種能夠治癒所有癌症的新型藥物，首批接受臨床試驗的19名晚期肝癌患者病情都有較大好轉。不僅如此，該公司稱，假以時日，這種藥物甚至有可能治癒一切疾病。
首批患者反應良好
今年4月，19名接受化療但沒有好轉的肝癌病人開始服用這種名為ALN-VSP的新型藥物。服用第一劑後的數周內，藥物就已經很明顯地開始阻止腫瘤產生自身生長需要的蛋白質。
到今年6月，阿爾尼拉姆公司稱，通過“喚醒”人體自身的一種很少使用的免疫防禦系統，ALN-VSP成功切斷肝癌患者體內腫瘤62%的血流量。在治療肝癌時，傳統藥物一般使用消除致病蛋白質的方法，而ALN-VSP則通過核糖核酸干擾(RNAi)療法直接阻止細胞生成致病蛋白質。
喚醒人體自身防禦機制
科學家在研究中還發現核糖核酸(RNA)和去氧核糖核酸(DNA)之間一個奇妙的聯繫———如果說DNA對蛋白質來說是一張圖紙，那麼RNA就是能夠下達指令的建築商。RNA把DNA上的基因複製成單鏈的信使RNA，再由它向細胞傳遞資訊繼而產生蛋白質。
1998年，科學家發現了核糖核酸干擾(RNAi)機制，原始生物就利用這個系統來甄別和摧毀病毒雙鏈RNA和病毒信使RNA。研究人員發現，將一小段雙鏈RNA引入細胞即能觸發這一埋藏在人體內的古老機制，使RNAi再次發揮停止生產特定蛋白質的功效。從這一角度看，可以說RNAi具有治癒包括癌症在內的許多疾病的能力，這些疾病的特點一般都是由病變細胞產生過量的常見蛋白質所致。從理論上說，操控RNAi來殺死蛋白質並不難。比方說，ALN-VSP內就含有合成的雙鏈RNA，它與肝臟腫瘤用於編碼兩種蛋白質的信使RNA相匹配，那兩種蛋白質分別是促進腫瘤血管生長的血管內皮生長因數(VEGF)和加速腫瘤細胞快速分裂的紡錘體驅動蛋白(KSP)。
合成的雙鏈RNA進入肝細胞後，人體內的RNAi機制便會摧毀合成的RNA和任何與之匹配的、與腫瘤生長相關的信使RNA，阻止蛋白質的繼續產生，從而使腫瘤停止生長。
有望“包治百病”
除了在癌症領域的應用，這項能攻擊單個基因的技術還在其它醫學領域掀起一陣RNAi療法旋風。目前，阿爾尼拉姆公司已經將這種療法用於亨廷頓氏舞蹈症、視網膜黃斑變性、肌肉萎縮和愛滋病等疾病的研究。
核磁共振掃描顯示，使用ALN-VSP療法後，肝臟腫瘤中的血流量明顯減少
加利福尼亞州知名分子遺傳學家約翰・羅西稱，RNAi療法有望在兩年內成熟。由於首批試驗效果相當好，ALN-VSP有望成為首批基於RNAi理論而推向市場的藥物。羅西表示：“我認為RNAi療法對所有的病都有效。”
评论
太好了，举天同庆啊！！！！
评论
好消息
评论
不是愚人节？
评论
应该是真的，只是在2012年，还是很有希望：
ALN-VSP: Liver Cancers
Alnylam has advanced its RNAi therapeutic, ALN-VSP, into the clinic for the treatment of liver cancers and potentially other solid tumors with liver involvement.
ALN-VSP targets two key genes each involved in the disease pathway of liver cancer: kinesin spindle protein, or KSP is involved in cancer proliferation, and vascular endothelial growth factor, or VEGF, is involved in the growth of new blood vessels that feed tumors. We believe that a dual-target approach in cancer increases the potential for a significant therapeutic benefit.
In April 2009, Phase I clinical trials were initiated for ALN-VSP. Results of this trial were presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting early June 2011. ALN-VSP is Alnylam's first systemic RNAi program and the Phase I trial results represent an important milestone in the advancement of RNAi therapeutics. Data demonstrate for the first time both clinical activity and RNAi mechanism for an RNAi therapeutic.
The Phase I study showed that ALN-VSP was generally well tolerated. ALN-VSP was administered to 41 patients at doses ranging from 0.1 to 1.5 mg/kg; a total of 209 doses have been administered, with a range of 1 to 28 doses per patient. Based the safety data, the recommended dose for advancement of ALN-VSP into Phase II studies is 1.0 mg/kg. In this study, 29 tumor biopsies were obtained voluntarily from 15 patients across multiple dose levels (from 0.4 to 1.5 mg/kg) using a CT-guided procedure; these included hepatic (liver) tumor biopsies from 11 patients and extra-hepatic tumor biopsies from four patients. The two siRNAs targeting VEGF and KSP that comprise ALN-VSP were detected in nearly all of the biopsy samples evaluable for drug levels at siRNA concentrations ranging from 0.3 to 142 ng/g tissue. These levels of siRNA are pharmacologically relevant since pre-clinical studies have shown that siRNA tissue levels of 1 ng/g are associated with 50% target gene silencing (Landesman et al., Silence, 1:16, 2010).
In June 2012, results from our Phase I extension study were presented at the ASCO Annual Meeting. These data include safety and tolerability of multiple doses of ALN-VSP, as well as evidence for anti-tumor activity in this very advanced, heavily pre-treated cancer patient population. Multiple patients achieved stable disease or better, including a patient with endometrial cancer metastatic to the liver who achieved a complete response. Results from the extension study also give us increased confidence in long-term chronic dosing with RNAi therapeutics delivered via LNPs, as patients have received drug twice a month for up to nearly two years, and approximately 11 months on average. In this study, chronic dosing of up to 23 months with ALN-VSP was found to be generally safe and well tolerated.
The drug is formulated using a first generation lipid nanoparticle developed by Tekmira Pharmaceuticals Corporation. The ALN-VSP program is partnered with Ascletis for HCC in China, and Alnylam will retain all rights in the rest of the world.
评论
惨了. I am the lengend 要来了.
评论
真的假的？
评论
应该是真的，只是在2012年，还是很有希望：
ALN-VSP: Liver Cancers
Alnylam has advanced its RNAi therapeutic, ALN-VSP, into the clinic for the treatment of liver cancers and potentially other solid tumors with liver involvement.
ALN-VSP targets two key genes each involved in the disease pathway of liver cancer: kinesin spindle protein, or KSP is involved in cancer proliferation, and vascular endothelial growth factor, or VEGF, is involved in the growth of new blood vessels that feed tumors. We believe that a dual-target approach in cancer increases the potential for a significant therapeutic benefit.
In April 2009, Phase I clinical trials were initiated for ALN-VSP. Results of this trial were presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting early June 2011. ALN-VSP is Alnylam's first systemic RNAi program and the Phase I trial results represent an important milestone in the advancement of RNAi therapeutics. Data demonstrate for the first time both clinical activity and RNAi mechanism for an RNAi therapeutic.
The Phase I study showed that ALN-VSP was generally well tolerated. ALN-VSP was administered to 41 patients at doses ranging from 0.1 to 1.5 mg/kg; a total of 209 doses have been administered, with a range of 1 to 28 doses per patient. Based the safety data, the recommended dose for advancement of ALN-VSP into Phase II studies is 1.0 mg/kg. In this study, 29 tumor biopsies were obtained voluntarily from 15 patients across multiple dose levels (from 0.4 to 1.5 mg/kg) using a CT-guided procedure; these included hepatic (liver) tumor biopsies from 11 patients and extra-hepatic tumor biopsies from four patients. The two siRNAs targeting VEGF and KSP that comprise ALN-VSP were detected in nearly all of the biopsy samples evaluable for drug levels at siRNA concentrations ranging from 0.3 to 142 ng/g tissue. These levels of siRNA are pharmacologically relevant since pre-clinical studies have shown that siRNA tissue levels of 1 ng/g are associated with 50% target gene silencing (Landesman et al., Silence, 1:16, 2010).
In June 2012, results from our Phase I extension study were presented at the ASCO Annual Meeting. These data include safety and tolerability of multiple doses of ALN-VSP, as well as evidence for anti-tumor activity in this very advanced, heavily pre-treated cancer patient population. Multiple patients achieved stable disease or better, including a patient with endometrial cancer metastatic to the liver who achieved a complete response. Results from the extension study also give us increased confidence in long-term chronic dosing with RNAi therapeutics delivered via LNPs, as patients have received drug twice a month for up to nearly two years, and approximately 11 months on average. In this study, chronic dosing of up to 23 months with ALN-VSP was found to be generally safe and well tolerated.
The drug is formulated using a first generation lipid nanoparticle developed by Tekmira Pharmaceuticals Corporation. The ALN-VSP program is partnered with Ascletis for HCC in China, and Alnylam will retain all rights in the rest of the world.
评论
治愈不大可能，对某种癌症有疗效倒有可能
评论
真是好消息啊
评论
希望药品尽快推出市场
评论
此次人可以长生不老了
评论
连着3次去看，是不是在大千里，确认不是！ 高兴
评论
大Ｖ
评论
期待
评论
评论
我阿姨刚诊断出是肺癌，希望药品快点推出吧
评论
评论
如果是真的就太好了
评论
如果艾滋病攻克了，人类岂不是可以放心乱搞不带套了?
评论
地球要承受不了了，像月球出发吧。
评论
科学家好厉害啊
评论
如果是真的，应该可以得诺贝尔医学奖了吧~
评论
10年就有新闻了，不知现在研究进展如何
评论
那以后还有人死亡吗？
评论
评论
不大相信。按照能量守恒定律或者热量或者其他定律来说，如果没有癌症，艾滋之类的疾病，人类会更加肆无忌惮的对地球，对环境破坏，更早灭亡。
评论
今天都是大新闻，开车抢银行的，李亚鹏王菲离婚的，攻克癌症的.....
凡是必有联系，仔细想想有无内在联系....
评论
今天十三号 星期五。。
评论
Hope it is the true drug.
澳洲中文论坛热点
- 新西兰总理：出世在新西兰的新纳粹Thomas Sewell是“挺蹩脚的人”，但那是澳洲的问题
- 新西兰总理拉克森称新纳粹Thomas Sewell是坏人，但是没对要求把他从澳大利亚遣返到诞生国去的呼吁置评。
- 撞穿学校栅栏害死十一岁男孩的司机不必坐牢
- 一位女司机撞穿学校栅栏、害死了11岁男孩，被罚2000元罚金、撤消驾照，不必坐牢。Jack Davey 的父母去了